HL036 ophthalmic solution

BIOLOGICAL2 trials

Sponsors

HanAll BioPharma Co., Ltd.

Conditions

Dry Eye

Phase 2

A Study to Assess Efficacy of HL036 in Subjects With Dry Eyes

CompletedNCT03334539

HanAll BioPharma Co., Ltd.Dry Eye

Start: 2017-11-05End: 2018-04-09Updated: 2024-03-07

Phase 3

A Study to Assess Efficacy and Safety of HL036 in Subjects With Dry Eyes

CompletedNCT03846453

HanAll BioPharma Co., Ltd.Dry Eye

Start: 2019-03-10End: 2019-11-22Updated: 2022-04-14

Related Papers

TNF-α inhibitor tanfanercept (HBM9036) improves signs and symptoms of dry eye in a phase 2 trial in the controlled adverse environment in China.

2022-02-2222 citations